BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Breast cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Diagnosis
1435 results:

  • 1. CDH1 Genotype Exploration in Women With Hereditary Lobular breast cancer Phenotype.
    Corso G; Marino E; Zanzottera C; Oliveira C; Bernard L; Macis D; Figueiredo J; Pereira J; Carneiro P; Massari G; Barberis M; De Scalzi AM; Taormina SV; Sajjadi E; Sangalli C; Gandini S; D'Ecclesiis O; Trovato CM; Rotili A; Pesapane F; Nicosia L; La Vecchia C; Galimberti V; Guerini-Rocco E; Bonanni B; Veronesi P
    JAMA Netw Open; 2024 Apr; 7(4):e247862. PubMed ID: 38652475
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Postpartum breast cancer and Survival in Women With Germline BRCA Pathogenic Variants.
    Zhang Z; Ye S; Bernhardt SM; Nelson HD; Velie EM; Borges VF; Woodward ER; Evans DGR; Schedin PJ
    JAMA Netw Open; 2024 Apr; 7(4):e247421. PubMed ID: 38639936
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. cancer genetic counselling for hereditary breast cancer in the era of precision oncology.
    Pensabene M; Calabrese A; von Arx C; Caputo R; De Laurentiis M
    Cancer Treat Rev; 2024 Apr; 125():102702. PubMed ID: 38452709
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Central nervous system metastases in breast cancer patients with germline BRCA pathogenic variants compared to non-carriers: a matched-pair analysis.
    Ben-Zion Berliner M; Yust-Katz S; Lavie I; Goldberg Y; Kedar I; Yerushalmi R
    BMC Cancer; 2024 Feb; 24(1):219. PubMed ID: 38365640
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Challenges to genetic testing for germline mutations associated with breast cancer among African Americans Authors.
    Kamaraju S; Conroy M; Harris A; Georgen M; Min H; Powell M; Kurzrock R
    Cancer Treat Rev; 2024 Mar; 124():102695. PubMed ID: 38325071
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Natural History of Germline brca1 Mutated and BRCA Wild-type Triple-negative breast cancer.
    Gardi N; Chaubal R; Parab P; Pachakar S; Kulkarni S; Shet T; Joshi S; Kembhavi Y; Chandrani P; Quist J; Kowtal P; Grigoriadis A; Sarin R; Govindarajan R; Gupta S
    Cancer Res Commun; 2024 Feb; 4(2):404-417. PubMed ID: 38315150
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. [A Case of Recurrent breast cancer That Was brca1 Pathogenic Variant-Positive Successfully Treated with PARP Inhibitor].
    Aoyagi T; Namura M; Sakata H; Tamanuki T; Iwai M; Iwata K; Takahashi H; Matsuzaki H
    Gan To Kagaku Ryoho; 2023 Dec; 50(13):1462-1464. PubMed ID: 38303308
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Investigation of Genetic Alterations Associated With Interval breast cancer.
    Rodriguez J; Grassmann F; Xiao Q; Eriksson M; Mao X; Bajalica-Lagercrantz S; Hall P; Czene K
    JAMA Oncol; 2024 Mar; 10(3):372-379. PubMed ID: 38270937
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Does Early Olaparib Administration Improve Prognosis in Patients with HER2-Negative Metastatic breast cancer and brca1 and/or BRCA2 Pathogenic Variants?-A Case Report].
    Takuwa H; Sasaki S; Yamada T; Takeuchi M
    Gan To Kagaku Ryoho; 2023 Dec; 50(12):1295-1299. PubMed ID: 38247067
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Establishing the role of brca1 in the diagnosis, prognosis and immune infiltrates of breast invasive cancer by bioinformatics analysis and experimental validation.
    Li L; Li S; Zhang X; Mei L; Fu X; Dai M; Wei N
    Aging (Albany NY); 2024 Jan; 16(2):1077-1095. PubMed ID: 38224491
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Long-term outcomes of young, node-negative, chemotherapy-naïve, triple-negative breast cancer patients according to brca1 status.
    Wang Y; Dackus GMHE; Rosenberg EH; Cornelissen S; de Boo LW; Broeks A; Brugman W; Chan TWS; van Diest PJ; Hauptmann M; Ter Hoeve ND; Isaeva OI; de Jong VMT; Jóźwiak K; Kluin RJC; Kok M; Koop E; Nederlof PM; Opdam M; Schouten PC; Siesling S; van Steenis C; Voogd AC; Vreuls W; Salgado RF; Linn SC; Schmidt MK
    BMC Med; 2024 Jan; 22(1):9. PubMed ID: 38191387
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Screening Programs for breast cancer: Toward Individualized, Risk-Adapted Strategies of Early Detection.
    Trapani D; Sandoval J; Aliaga PT; Ascione L; Maria Berton Giachetti PP; Curigliano G; Ginsburg O
    Cancer Treat Res; 2023; 188():63-88. PubMed ID: 38175342
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. brca1 and BRCA2 germline mutations in Chinese Hakka breast cancer patients.
    Zhang Y; Wu H; Gan C; Rao H; Wang Q; Guo X
    BMC Med Genomics; 2024 Jan; 17(1):3. PubMed ID: 38167124
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A case of simultaneous breast cancer and ovarian cancer based on a hereditary breast and ovarian cancer syndrome.
    Kotaka S; Yasui H; Tsubouchi H; Mori M; Kotani H; Yoshimura A; Ouchi A; Okuno M; Komori K; Shimizu Y; Suzuki S
    Nagoya J Med Sci; 2023 Nov; 85(4):814-821. PubMed ID: 38155625
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. The Potential of Genetics in Identifying Women at Lower Risk of breast cancer.
    Bolze A; Cirulli ET; Hajek C; Schnell Blitstein JM; Grzymski JJ
    JAMA Oncol; 2024 Feb; 10(2):236-239. PubMed ID: 38153744
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Pregnancy After breast cancer in Young BRCA Carriers: An International Hospital-Based Cohort Study.
    Lambertini M; Blondeaux E; Agostinetto E; Hamy AS; Kim HJ; Di Meglio A; Bernstein Molho R; Hilbers F; Pogoda K; Carrasco E; Punie K; Bajpai J; Ignatiadis M; Moore HCF; Phillips KA; Toss A; Rousset-Jablonski C; Peccatori FA; Renaud T; Ferrari A; Paluch-Shimon S; Fruscio R; Cui W; Wong SM; Vernieri C; Ruddy KJ; Dieci MV; Matikas A; Rozenblit M; Villarreal-Garza C; De Marchis L; Del Mastro L; Puglisi F; Del Pilar Estevez-Diz M; Rodriguez-Wallberg KA; Mrinakova B; Meister S; Livraghi L; Clatot F; Yerushalmi R; De Angelis C; Sánchez-Bayona R; Meattini I; Cichowska-Cwalinska N; Berlière M; Salama M; De Giorgi U; Sonnenblick A; Chiodi C; Lee YJ; Maria C; Azim HA; Boni L; Partridge AH;
    JAMA; 2024 Jan; 331(1):49-59. PubMed ID: 38059899
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study.
    Blansky D; Ansari N; Gao L; Sokol ES; Sivakumar S; Huang RSP; Pelletier M; Levy M; Pavlick D; Danziger N; Ross JS; Lustberg M; Rozenblit M
    Breast Cancer Res Treat; 2024 Feb; 204(1):181-185. PubMed ID: 37999916
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Rate of Pathogenic Germline Variants in Patients With Lung cancer.
    Sorscher S; LoPiccolo J; Heald B; Chen E; Bristow SL; Michalski ST; Nielsen SM; Lacoste A; Keyder E; Lee H; Nussbaum RL; Martins R; Esplin ED
    JCO Precis Oncol; 2023 Sep; 7():e2300190. PubMed ID: 37992258
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Research progress of good markers for canine mammary carcinoma.
    Yang NY; Zheng HH; Yu C; Ye Y; Du CT; Xie GH
    Mol Biol Rep; 2023 Dec; 50(12):10617-10625. PubMed ID: 37943402
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Specialty Care and Counselling about Hereditary cancer Risk Improves Adherence to cancer Screening and Prevention in Newfoundland and Labrador Patients with
    Roebothan A; Smith KN; Seal M; Etchegary H; Dawson L
    Curr Oncol; 2023 Oct; 30(10):9367-9381. PubMed ID: 37887578
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 72.